Top

Supportive Care in Cancer

Published in:

01-04-2015 | Original Article

Assessment of radiation-induced xerostomia: validation of the Italian version of the xerostomia questionnaire in head and neck cancer patients

Authors: Federica Pellegrino, Elena Groff, Luca Bastiani, Bruno Fattori, Guido Sotti

Published in: Supportive Care in Cancer | Issue 4/2015

Abstract

Purpose

Xerostomia is the most common acute and late side effect of radiation treatment for head and neck cancer. Affecting taste perception, chewing, swallowing and speech, xerostomia is also the major cause of decreased quality of life. The aims of this study were to validate the Italian translation of the self-reported eight-item xerostomia questionnaire (XQ) and determine its psychometric properties in patients treated with radiotherapy for head and neck cancer.

Methods

An observational cross-sectional study was conducted in the Radiotherapy Unit of the Veneto Institute of Oncology – IOV in Padua. The XQ was translated according to international guidelines and filled out by 102 patients. Construct validity was assessed using principal component analysis, internal consistency using Cronbach’s α coefficient and test-retest reliability at 1-month interval using the intraclass correlation coefficient (ICC). Criterion-related validity was evaluated to compare the Italian version of XQ with the European Organization for Research and Treatment of Cancer (EORTC) Core Quality-of-Life Questionnaire (QLQ-C30) and its Head and Neck Cancer Module (QLQ-H&N35).

Results

Cronbach’s α for the Italian version of XQ was strong at α = 0.93, test-retest reliability was also strong (0.79) and factor analysis confirmed that the questionnaire was one-dimensional. Criterion-related validity was excellent with high association with the EORTC QLQ-H&N35 xerostomia and sticky saliva scales.

Conclusions

The Italian version of XQ has excellent psychometric properties and can be used to evaluate the impact of emerging radiation delivery techniques aiming at preventing xerostomia.

I numeri del cancro in Italia 2013 [http://www.registri-tumori.it/PDF/AIOM2013/I_numeri_del_cancro_2013.pdf].

Langendijk JA, Doornaert P, Verdonack-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ (2008) Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26:3770–3776CrossRefPubMed

Eisbruch A, Rhodus N, Rosenthal D, Murphy B, Rasch C, Sonis S, Scarantino C, Brizel D (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13:226–234CrossRefPubMed

Jo D, Moiseenko V, Marks L, Chao C, Nam J, Eisbruch A (2010) Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol 76(1):S58–S63

Vissink A, Jansma J, Spijkervet FKL, Buriage FR, Coppes RP (2003) Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14(3):199–212CrossRefPubMed

Cheng SCH, Wu VWC, Kwong DLW, Ying MTC (2011) Assessment of post-radiotherapy salivary gland. Br J Radiol 84:393–402CrossRefPubMedCentralPubMed

Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A (2006) Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol 60(2):445–453CrossRef

Eisbruch A, Kim HM, Terrel JE, Marsh LH, Dawson LA, Ship JA (2001) Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol 50(3):695–704CrossRef

Lin SC, Jen YM, Chang YC, Lin CC (2008) Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiotherapy, and validation of the Taiwanese version of the xerostomia questionnaire. J Pain Symptom Manag 36(2):141–148CrossRef

10.

Marucci L, Marzi S, Sperduti I, Giovinazzo G, Pinnarò P, Benassi M, Strigari L (2012) Influence of intensity-modulated radiation therapy technique on xerostomia and related quality of life in patients treated with intensity-modulated radiation therapy for nasopharyngeal cancer. Head Neck 34(3):328–335CrossRefPubMed

11.

Jabbari S, Kim HM, Feng M, Lin A, Tsien C, Elshaikh M, Terrel E, Murdoch-Kinch C, Eisbruch A (2005) Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol 63(3):725–731CrossRef

12.

Pacholke HD, Amdur RJ, Morris CG, Li JG, Dempsey JF, Hinerman RW, Mendenhall WM (2005) Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy. Am J Clin Oncol 28:351–358CrossRefPubMed

13.

Guillemin F, Bombardier C, Beaton D (1993) Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 46:1417–1432CrossRefPubMed

14.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376CrossRefPubMed

15.

Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van Pottelsberghe C, Curran D, Ahlner-Elmqvist M, Maher EJ, Meyza JW, Brédart A, Söderholm AL, Arraras JJ, Feine JS, Abendstein H, Morton RP, Pignon T, Huguenin P, Bottomly A, Kaasa S (2000) A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 36:1796–1807CrossRefPubMed

16.

Nunnely JC, Bernstein IH (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York

17.

Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:297–334CrossRef

18.

Jensen SB, Pedersen AML, Vissink A, Andersen E, Brown CG, Davies AN et al (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18:1039–1060CrossRefPubMed

19.

Kaiser H (1970) A second generation little jiffy. Psychometrika 35:401–415CrossRef

20.

Cattell R (1966) The screen test for the number of factors. Multivar Behav Res 1:245–276CrossRef

21.

Lin A, Kim HM, Terrel JE, Dawson LA, Ship JA, Eisbruch A (2003) Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol 57:61–70CrossRef

22.

Beetz I, Burlage FR, Bijl HP, Hoegen-Chouvalova O, Christianen M, Vissink A, van der Laan B, de Bock G, Langendijk JA (2010) The Groningen radiotherapy-induced xerostomia questionnaire: development and validation of a new questionnaire. Radiother Oncol 97:127–131CrossRefPubMed

23.

Nutting CM, Morden JP, Harrington KJ et al (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12:127–136CrossRefPubMedCentralPubMed

24.

Kakoei S, Haghdoost AA, Rad M, Mohammadalizadch S, Pourdamghan N, Nakhaei M, Bahador M (2012) Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients. Arch Iran Med 15(4):214–218PubMed

25.

Beetz I, Schilstra C, Burlage FR, Koken PW, Doornaert P, Bijl HP, Chouvalova O, Leemans CR, de Bock GH, Christianen ME, van der Laan BF, Vissink A, Steenbakkers RJ, Lamgedijk JA (2012) Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors. Radiother Oncol 105:86–93CrossRefPubMed

26.

Little M, Schipper M, Feng FY, Vineberg K, Cornwall C, Murdoch-Kinch AC, Eisbruch A (2012) Reducing xerostomia after chemo-IMRT for head and neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys 83(3):1007–1014CrossRefPubMedCentralPubMed

27.

Citak E, Tulek Z (2013) Longitudinal quality of life in Turkish patients with head and neck cancer undergoing radiotherapy. Support Care Cancer 21:2171–2183CrossRefPubMed

Title: Assessment of radiation-induced xerostomia: validation of the Italian version of the xerostomia questionnaire in head and neck cancer patients
Authors: Federica Pellegrino
Elena Groff
Luca Bastiani
Bruno Fattori
Guido Sotti
Publication date: 01-04-2015
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 4/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2438-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2015

C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms

Role of stereotactic body radiotherapy for symptom control in head and neck cancer patients

The initial clinical interview—can it reduce cancer patients’ fear?

Identifying clinical and support service resources and network practices for cancer patients and survivors in southern Puerto Rico

Dietary habits changes and quality of life in patients undergoing chemotherapy for epithelial ovarian cancer

Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients’ relational autonomy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer